Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Martha Sajatovic, Thomas R Thompson, Kevin Nanry, Suzanne Edwards & Ranjani Manjunath. (2013) Prospective, open-label trial measuring satisfaction and convenience of two formulations of lamotrigine in subjects with mood disorders. Patient Preference and Adherence 7, pages 411-417.
Read now
Read now
Akhila Balasubramanian, M Alan Brookhart, Vamshidar Goli & Cathy W Critchlow. (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. International Journal of General Medicine 6, pages 839-848.
Read now
Read now
Mary K. Beard. (2012) Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference. Current Medical Research and Opinion 28:1, pages 141-147.
Read now
Read now
Kate Van Brunt, Louis S Matza, Peter M Classi & Joseph A Johnston. (2011) Preferences related to attention-deficit/hyperactivity disorder and its treatment. Patient Preference and Adherence 5, pages 33-43.
Read now
Read now
Raymond E. Cole. (2011) Clinical Strategies to Address Patients' Concerns in Osteoporosis Management with Bisphosphonates. Postgraduate Medicine 123:2, pages 131-144.
Read now
Read now
Véronique Rabenda & Jean-Yves Reginster. (2010) Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 677-689.
Read now
Read now
Kristina Casadei & Carolyn Becker. (2009) Once-monthly risedronate for postmenopausal osteoporosis. International Journal of Women's Health 1, pages 1-9.
Read now
Read now
Steven Boonen. (2009) Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective. Current Medical Research and Opinion 25:10, pages 2335-2341.
Read now
Read now
Deborah T. Gold, Haian Trinh & Wael Safi. (2009) Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Current Medical Research and Opinion 25:8, pages 1831-1839.
Read now
Read now
Jean-Yves Reginster, Audrey Neuprez & Olivier Bruyère. (2008) Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology 4:7, pages 941-951.
Read now
Read now
Andrea J. Singer & Steven Boonen. (2008) Osteoporosis management: translating research into optimal fracture protection II. Current Medical Research and Opinion 24:6, pages 1789-1796.
Read now
Read now
María J Moro-Álvarez & Manuel Díaz-Curiel. (2008) Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis. Clinical Interventions in Aging 3:2, pages 227-232.
Read now
Read now
Oliver Bock & Dieter Felsenberg. (2008) Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice. Clinical Interventions in Aging 3:2, pages 279-297.
Read now
Read now
Articles from other publishers (53)
Faisal I. Almohaileb & Zafar Rasheed. (2022) Comparing the Efficacies of Bisphosphonates’ Therapies for Osteoporosis Persistence and Compliance: A Systematic Review. Current Molecular Medicine 22:3, pages 274-284.
Crossref
Crossref
Laura Canals-Ruiz, Marta Comellas & Luís Lizán. (2021) Preferences, satisfaction and decision-making processes in osteoporosis treatment: a systematic review of the literature. Journal of Comparative Effectiveness Research 10:8, pages 629-645.
Crossref
Crossref
Deborah T. Gold. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1695
1707
.
Ashlyn A Swafford, Jamy D Ard, Daniel P Beavers, Peri C Gearren, Adolfo Z Fernandez, Sherri A Ford, Katelyn A Greene, Daniel E Kammire, Beverly A Nesbit, Kylie K Reed, Ashley A Weaver & Kristen M Beavers. (2020) Risedronate to Prevent Bone Loss After Sleeve Gastrectomy: Study Design and Feasibility Report of a Pilot Randomized Controlled Trial. JBMR Plus 4:10.
Crossref
Crossref
Michael R. McClung & Frank H. Ebetino. (2020) History of risedronate. Bone 137, pages 115407.
Crossref
Crossref
C. T. Yeam, S. Chia, H. C. C. Tan, Y. H. Kwan, W. Fong & J. J. B. Seng. (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporosis International 29:12, pages 2623-2637.
Crossref
Crossref
Ott Laius, Heti Pisarev, Katre Maasalu, Sulev Kõks & Aare Märtson. (2017) Adherence to osteoporosis medicines in Estonia—a comprehensive 15-year retrospective prescriptions database study. Archives of Osteoporosis 12:1.
Crossref
Crossref
L. Chou, P. Shamdasani, A. M. Briggs, F. M. Cicuttini, K. Sullivan, K. L. M. D. Seneviwickrama & A. E. Wluka. (2017) Systematic scoping review of patients’ perceived needs of health services for osteoporosis. Osteoporosis International 28:11, pages 3077-3098.
Crossref
Crossref
Edward Roddy, Sara Muller, Zoe Paskins, Samantha L. Hider, Milisa Blagojevic-Bucknall & Christian D. Mallen. (2017) Incident acute pseudogout and prior bisphosphonate use. Medicine 96:12, pages e6177.
Crossref
Crossref
Sophie Boudriau, Cecilia Hanzel, Julie Massicotte, Laura Sayegh, Jing Wang & Marc Lefebvre. (2016) Randomized Comparative Bioavailability of a Novel Three-Dimensional Printed Fast-Melt Formulation of Levetiracetam Following the Administration of a Single 1000-mg Dose to Healthy Human Volunteers Under Fasting and Fed Conditions. Drugs in R&D 16:2, pages 229-238.
Crossref
Crossref
Deborah T. Gold. 2016. The Duration and Safety of Osteoporosis Treatment. The Duration and Safety of Osteoporosis Treatment
239
253
.
Hideaki Kishimoto & Masayuki Maehara. (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Archives of Osteoporosis 10:1.
Crossref
Crossref
Mickaël Hiligsmann, Sandrine P. G. Bours & Annelies Boonen. (2015) A Review of Patient Preferences for Osteoporosis Drug Treatment. Current Rheumatology Reports 17:9.
Crossref
Crossref
K. Ganda, A. Schaffer, S. Pearson & M. J. Seibel. (2014) Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporosis International 25:4, pages 1345-1355.
Crossref
Crossref
David L. Kendler, David Macarios, Michael J. Lillestol, Alfred Moffett, Sacha Satram-Hoang, Joice Huang, Primal Kaur, En-Tzu Tang, Rachel B. Wagman & Rob Horne. (2014) Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause 21:1, pages 25-32.
Crossref
Crossref
Deborah T. Gold. 2013. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
448
454
.
Yesim Gokce Kutsal, Nurten Eskiyurt, Jale Irdesel, Vesile Sepici, Hatice Ugurlu, Yesim Kirazli, Fusun Ardic, Mirko Korsic, Tonko Vlak, Mane Grlickov, Snezana Markovic Temelkova, Miroslav Lazarov, Nada Pilipovic, Vera Popovic, Aleksandar Dimic, Branka Kovacev, Dorina Ruci, Argjend Tafaj, Elma Kucukalic-Selimovic, Dijana Avdic, Hajrija Seleskovic, Snjezana Pejicic, Bulent Butun, Gulseren Akyuz, Lale Cerrahoglu, Omer Faruk Sendur, Peyman Yalcin, Sema Oncel, Merih Saridogan, Tunay Sarpel, Mehmet Tosun, Kazim Senel, Savas Gursoy, Ferhan Canturk, Huseyin Demir, Blazenka Miskic, Dalibor Krpan, Franjo Skreb, Simeon Grazio, Zeljka Crncevic-Orlic, Fatih Ozdener & Hakan Oncel. (2013) A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study. Health 05:07, pages 30-40.
Crossref
Crossref
Deborah T. Gold. 2013. Osteoporosis. Osteoporosis
1909
1921
.
Michael R. McClung, Claude-Laurent Benhamou, Zulema Man, Witold Tlustochowicz, Jose R. Zanchetta, Rachelle Eusebio, Ana M. Balske, Ellen Matzkin, Wojciech P. Olszynski, Robert Recker & Pierre D. Delmas. (2012) A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data. Calcified Tissue International 92:1, pages 59-67.
Crossref
Crossref
Sonya J. Snedecor, John A. Carter, Satyin Kaura & Marc F. Botteman. (2012) Cost-Effectiveness of Denosumab Versus Zoledronic Acid in the Management of Skeletal Metastases Secondary to Breast Cancer. Clinical Therapeutics 34:6, pages 1334-1349.
Crossref
Crossref
E. Barrett-Connor, S. W. Wade, T. P. Do, S. Satram-Hoang, R. Stewart, G. Gao & D. Macarios. (2011) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™. Osteoporosis International 23:2, pages 733-741.
Crossref
Crossref
Deborah T. Gold, Rob Horne, Cheryl D. Coon, Mark A. Price, Jeff Borenstein, Sepideh F. Varon, Sacha Satram-Hoang & David Macarios. (2011) Development, Reliability, and Validity of a New Preference and Satisfaction Questionnaire. Value in Health 14:8, pages 1109-1116.
Crossref
Crossref
J.-F. Brantus, C. Roemer-Becuwe, P. Cony-Makhoul, S. Salino, A. Fontana, P. Debourdeau, T. Thomas, J.-P. Guastalla, H. Ghesquieres, C. Sebban, M. Pavic, P. Collet, J.-P. Larbre, S. Martinon, F. Brocard, A.-G. Bodard, G. Blanc, V. Balestrière, B. Favier, F. Farsi, I. Krakowski & P. Biron. (2011) Guide de recommandations d’utilisation des bisphosphonates dans les lésions osseuses malignes des tumeurs solides et du myélome multiple. La Revue de Médecine Interne 32:8, pages 494-505.
Crossref
Crossref
D. L. Kendler, M. R. McClung, N. Freemantle, M. Lillestol, A. H. Moffett, J. Borenstein, S. Satram-Hoang, Y.-C. Yang, P. Kaur, D. Macarios & S. Siddhanti. (2010) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporosis International 22:6, pages 1725-1735.
Crossref
Crossref
Deborah T. Gold. (2011) Understanding Patient Compliance and Persistence with Osteoporosis Therapy. Drugs & Aging 28:4, pages 249-255.
Crossref
Crossref
S. Lee, P. Glendenning & C. A. Inderjeeth. (2010) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis International 22:3, pages 741-753.
Crossref
Crossref
A. Sicras Mainar, R. Navarro Artieda, L. Gutiérrez Nicuesa, F. Sorio Vilela & M. Intorcia. (2011) Persistencia en el tratamiento para la osteoporosis en pacientes posmenopáusicas en el ámbito de la Atención Primaria. Farmacéuticos de Atención Primaria 9:2, pages 46-53.
Crossref
Crossref
S. L. Silverman, J. T. Schousboe & D. T. Gold. (2010) Oral bisphosphonate compliance and persistence: a matter of choice?. Osteoporosis International 22:1, pages 21-26.
Crossref
Crossref
Stuart Silverman & Deborah T. Gold. (2010) Compliance and persistence with osteoporosis medications: A critical review of the literature. Reviews in Endocrine and Metabolic Disorders 11:4, pages 275-280.
Crossref
Crossref
Becky A. Briesacher, Susan E. Andrade, Leslie R. Harrold, Hassan Fouayzi & Robert A. Yood. (2010) Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiology and Drug Safety 19:12, pages 1233-1240.
Crossref
Crossref
Stuart L. Silverman. (2010) Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies. Calcified Tissue International 87:5, pages 375-384.
Crossref
Crossref
Kristi L. Ryzner, Jill S. Burkiewicz, Brooke L. Griffin & Kathy E. Komperda. (2010) Survey of Bisphosphonate Regimen Preferences in an Urban Community Health Center. The Consultant Pharmacist 25:10, pages 671-675.
Crossref
Crossref
Becky A. Briesacher, Susan E. Andrade, Leslie R. Harrold, Hassan Fouayzi & Robert A. Yood. (2010) Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence. The American Journal of Medicine 123:3, pages 275-280.
Crossref
Crossref
F.-E. Cotté, P. Fardellone, F. Mercier, A.-F. Gaudin & C. Roux. (2009) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporosis International 21:1, pages 145-155.
Crossref
Crossref
Valentina I. Petkov & Melissa I. Williams. 2010. Osteoporosis. Osteoporosis
605
620
.
E. Terpos, O. Sezer, P.I. Croucher, R. García-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Bladé, M. Cavo, M. Delforge, M.-A. Dimopoulos, T. Facon, M. Macro, A. Waage & P. Sonneveld. (2009) The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Annals of Oncology 20:8, pages 1303-1317.
Crossref
Crossref
C. Roerholt, P. Eiken & B. Abrahamsen. (2008) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporosis International 20:2, pages 299-307.
Crossref
Crossref
Jean-Yves ReginsterMickaël HiligsmannVéronique RabendaBrigitte ZegelsAudrey NeuprezOlivier Bruyere. (2009) Ibandronate in the Management of Postmenopausal Osteoporosis. Clinical Medicine. Therapeutics 1, pages CMT.S2354.
Crossref
Crossref
B.L. Clarke. (2009) Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users. Yearbook of Medicine 2009, pages 507-509.
Crossref
Crossref
B.L. Clarke. (2009) Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users. Yearbook of Endocrinology 2009, pages 167-168.
Crossref
Crossref
M. Sosa Henríquez & M.J. Gómez de Tejada Romero. (2009) La medicina basada en la evidencia y los fármacos aprobados para el tratamiento de la osteoporosis. Papel del calcio y la vitamina D. Revista Clínica Española 209:1, pages 25-36.
Crossref
Crossref
Elizabeth E. Roughead, Emmae Ramsay, Kym Priess, John Barratt, Philip Ryan & Andrew L. Gilbert. (2008) Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates. Pharmacoepidemiology and Drug Safety 18:1, pages 69-75.
Crossref
Crossref
Deborah T. Gold. 2008. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
254
256
.
Jeffrey R Curtis, Andrew O Westfall, Hong Cheng, Kenneth Lyles, Kenneth G Saag & Elizabeth Delzell. (2008) Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate Users. Journal of Bone and Mineral Research 23:9, pages 1435-1441.
Crossref
Crossref
P. D. Delmas, C. L. Benhamou, Z. Man, W. Tlustochowicz, E. Matzkin, R. Eusebio, J. Zanchetta, W. P. Olszynski, R. R. Recker & M. R. McClung. (2007) Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporosis International 19:7, pages 1039-1045.
Crossref
Crossref
Stuart L. Silverman & Deborah T. Gold. (2008) Compliance and persistence with osteoporosis therapies. Current Rheumatology Reports 10:2, pages 118-122.
Crossref
Crossref
M. Aapro, P.A. Abrahamsson, J.J. Body, R.E. Coleman, R. Colomer, L. Costa, L. Crinò, L. Dirix, M. Gnant, J. Gralow, P. Hadji, G.N. Hortobagyi, W. Jonat, A. Lipton, A. Monnier, A.H.G. Paterson, R. Rizzoli, F. Saad & B. Thürlimann. (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology 19:3, pages 420-432.
Crossref
Crossref
James E Frampton & Caroline M Perry. (2008) Ibandronate. Drugs 68:18, pages 2683-2707.
Crossref
Crossref
DEBORAH T. GOLD & SAMANTHA SOLIMEO. 2008. Osteoporosis. Osteoporosis
1547
1553
.
D.B. Kimmel. (2016) Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates. Journal of Dental Research 86:11, pages 1022-1033.
Crossref
Crossref
Hosam K. Kamel. (2007) Update on Osteoporosis Management in Long-term Care: Focus on Bisphosphonates. Journal of the American Medical Directors Association 8:7, pages 434-440.
Crossref
Crossref
J. A. Cramer, D. T. Gold, S. L. Silverman & E. M. Lewiecki. (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis International 18:8, pages 1023-1031.
Crossref
Crossref
Jesús Walliser Duarte, Susan C. Bolge & Shuvayu S. Sen. (2007) An Evaluation of patients' preferences for osteoporosis medications and their attributes: The PREFER-international study. Clinical Therapeutics 29:3, pages 488-503.
Crossref
Crossref